Medications

Weight Loss Drugs Diabetes Treatment GLP-1 Receptor Agonists GLP-1 Drugs Prescription Drugs Over-the-Counter Drugs Weight Loss Weight Management Diabetes Weight Loss Treatments

3 ARTICLES

last wk.

Statins Linked to Lower Risk of Open‑Angle Glaucoma

Large electronic‑health‑record analyses found reduced diagnoses and less need for stronger treatments, with authors calling for randomized trials to test causality.

3 ARTICLES

4w ago

Novartis’ Pelacarsen Fails Phase 3 Outcome Trial

4 ARTICLES

2mo ago

PAMI Raises Free-Medicine Income Ceilings and Buenos Aires Widens Provincial Drug Program

4 ARTICLES

2mo ago

Novo Nordisk Sues Eli Lilly Over Allegedly Misleading Weight-Loss and Diabetes Ads

4 ARTICLES

4mo ago

CVS Caremark Reverses Exclusion and Adds Lilly’s Foundayo and Zepbound to Its Formulary

4 ARTICLES

4mo ago

BMJ Study Ties GLP-1 Drugs to Lower Addiction Risk and Fewer Overdoses in VA Patients

8 ARTICLES

7mo ago

New Studies Refine GLP-1 Picture: Weight Rebounds After Stopping, With Hints of Lower Addiction Risk

8 ARTICLES

7mo ago

After Stopping GLP-1 Weight-Loss Drugs, Most Lost Weight Returns Within a Year, Analysis Finds

3 ARTICLES

7mo ago

German Endocrinologist Calls for Statutory Coverage of Weight-Loss Injections as Illegal Procurement Rises

4 ARTICLES

7mo ago

CDC Survey Finds Record Youth Obesity as Adult Rates Edge Lower

3 ARTICLES

8mo ago

Berlin Patient Begins Donanemab as Germany’s New Alzheimer Therapies Roll Out

3 ARTICLES

8mo ago

Boots' £10 Tuesday Cuts Plant Sterol Cholesterol Tablets to 17p Each

3 ARTICLES

8mo ago

Novo’s Wegovy Pill Posts Quick Uptake, Boosting Shares as Oral GLP‑1 Battle Nears

4 ARTICLES

9mo ago

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

5 ARTICLES

9mo ago

FDA Approves First Oral Wegovy Weight-Loss Pill as U.S. Availability Begins

Medications

Statins Linked to Lower Risk of Open‑Angle Glaucoma

Novartis’ Pelacarsen Fails Phase 3 Outcome Trial

PAMI Raises Free-Medicine Income Ceilings and Buenos Aires Widens Provincial Drug Program

Novo Nordisk Sues Eli Lilly Over Allegedly Misleading Weight-Loss and Diabetes Ads

CVS Caremark Reverses Exclusion and Adds Lilly’s Foundayo and Zepbound to Its Formulary

Hypothyroidism Slows Metabolism but Proper Treatment Lets Patients Lose Weight

Rio Inaugurates Super Health Center, Begins Ozempic Pilot in Public System

Rio to Offer Ozempic in Public Clinics Next Week as Paes Urges SUS Adoption

Eli Lilly to Invest $3 Billion in China to Build Orforglipron Manufacturing

Large VA Study Links GLP-1 Drugs to Lower Addiction Risk, Fewer Severe Outcomes

Never miss stories about

Medications

BMJ Study Ties GLP-1 Drugs to Lower Addiction Risk and Fewer Overdoses in VA Patients

New Studies Refine GLP-1 Picture: Weight Rebounds After Stopping, With Hints of Lower Addiction Risk

After Stopping GLP-1 Weight-Loss Drugs, Most Lost Weight Returns Within a Year, Analysis Finds

German Endocrinologist Calls for Statutory Coverage of Weight-Loss Injections as Illegal Procurement Rises

CDC Survey Finds Record Youth Obesity as Adult Rates Edge Lower

Berlin Patient Begins Donanemab as Germany’s New Alzheimer Therapies Roll Out

Boots' £10 Tuesday Cuts Plant Sterol Cholesterol Tablets to 17p Each

Novo’s Wegovy Pill Posts Quick Uptake, Boosting Shares as Oral GLP‑1 Battle Nears

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

FDA Approves First Oral Wegovy Weight-Loss Pill as U.S. Availability Begins

Never miss stories about

Medications